X4 Pharmaceuticals

About:

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

Website: https://www.x4pharma.com

Top Investors: Hercules Capital, OrbiMed, Cormorant Asset Management, New Enterprise Associates, SV Health Investors

Description:

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.